The obtained results on Protein C generation, clot-specific mode of action and thrombin inhibition exhibited by EGF-SK now need a detailed evaluation of this engineered molecule for ischemic stroke, apart from myocardial infarction, where, worldwide, there exists an acute and urgent need for newer and more effective thrombolyics without the side-effects seen with tPA and its new generation analogs [59]. Here, PLAT is linked to myocardial infarction.